[
  {
    "ts": null,
    "headline": "Biogen: EMA and FDA examine an enhanced dosage of Spinraza",
    "summary": "Biogen announces that the European Medicines Agency has agreed to review the marketing authorization application for a higher dosage regimen of nusinersen in the treatment of spinal muscular atrophy...",
    "url": "https://finnhub.io/api/news?id=7b5fb940513e1203ed428e0ea4098fedfeab2a432d43b1bcb69659bcda31eacb",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737696690,
      "headline": "Biogen: EMA and FDA examine an enhanced dosage of Spinraza",
      "id": 132453644,
      "image": "",
      "related": "BIIB",
      "source": "Finnhub",
      "summary": "Biogen announces that the European Medicines Agency has agreed to review the marketing authorization application for a higher dosage regimen of nusinersen in the treatment of spinal muscular atrophy...",
      "url": "https://finnhub.io/api/news?id=7b5fb940513e1203ed428e0ea4098fedfeab2a432d43b1bcb69659bcda31eacb"
    }
  }
]